Related Industry Reports:
- The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
- UpdatesPlus Nicotinic Receptors - Current Research and Development - February 2009
- The World Schizophrenia Market 2005-2010
- R&D Trends: Bipolar Disorders - Developments in schizophrenia dictate trends in diminutive bipolar disorders pipeline
- Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia
Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia: A Randomized, Double-blind, Risperidone-Compared Trial.
Clinical neuropharmacology 2010 Jul 1; 33(4):169-175
Yang J, Bahk W WM, Cho H HS, Jeon Y YW, Jon D DI, Jung H HY, Kim C CH, Kim H HC, Kim Y YK, Kim Y YH, Kwon J JS, Lee S SY, Lee S SH, Yi J JS, Yoon B BH, Kim S SH
*Department of Psychiatry, Korea University Guro Hospital; daggerDepartment of Psychiatry, St Mary's Hospital; double daggerDepartment of Psychiatry, Severance Mental Health Hospital; section signDepartment of Psychiatry, Our Lady of Mercy Hospital; paral
OBJECTIVES:: The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design. METHODS:: Patients aged 18 to 65 years with schizophrenia were randomly assigned to blonanserin or risperidone treatment for 8 weeks. The efficacy was assessed using the mean change in Positive and Negative Syndrome Scale score total scores from baseline to week 8. Safety assessments included monitoring of vital signs, a physical examination, laboratory tests, and adverse events. RESULTS:: Of 206 randomly enrolled patients, 103 receiving blonanserin and 103 receiving risperidone were included in the analysis. In this study, noninferiority between blonanserin and risperidone was demonstrated. The mean change in the Positive and Negative Syndrome Scale total score at the final evaluation time point was -23.48 +/- 19.73 for the blonanserin group and -25.40 +/- 18.38 for the risperidone group. Adverse events, which occurred less frequently in the blonanserin than in the risperidone group, included dysarthria (P = 0.0288), dizziness (P = 0.0139), increased alanine aminotransferase and aspartate aminotransferase (P = 0.0095 and P = 0.0032, respectively), and increased level blood prolactin (P = 0.0012). On the other hand, the adverse events that occurred more frequently in the blonanserin than in the risperidone group was hand tremor (P = 0.0006). CONCLUSIONS:: Blonanserin was effective in the treatment of Korean patients with schizophrenia compared with risperidone and was more tolerable with a better safety profile, particularly with respect to prolactin elevation. These findings suggest that blonanserin is useful in the treatment of schizophrenia.
Keywords: Blonanserin Schizophrenia Risperidone
